Clinical Report: Utilization of Perampanel for Seizures in Pediatric AE
Overview
This retrospective study evaluated the efficacy of perampanel (PER) in pediatric patients with autoimmune encephalitis (AE)-related seizures, involving 14 patients divided into two groups. Results indicated that PER may improve seizure outcomes in this population, with no serious adverse events reported.
Background
Autoimmune encephalitis (AE) is a significant cause of seizures in children, often leading to chronic epilepsy. Effective management of seizures in AE is crucial, as they can severely impact the quality of life. Current treatment options are limited, making the exploration of medications like perampanel particularly relevant.
Data Highlights
Group
Outcome
Percentage
ASSAE
Seizure resolution
42.8% (3/7)
AAE
≥ 50% reduction in seizure frequency
57.1% (4/7)
AAE
Seizure freedom
42.8% (3/7)
Key Findings
14 pediatric patients with AE (9 male, 5 female; median age 8.5 years) were treated with PER.
Median maintenance dose of PER ranged from 2 to 4 mg per day.
42.8% of patients in the ASSAE group achieved seizure resolution.
57.1% of patients in the AAE group had a ≥ 50% reduction in seizure frequency at 3 months.
42.8% of patients in the AAE group achieved seizure freedom at 3 months.
No serious adverse events were reported in either group.
Clinical Implications
The findings suggest that perampanel may be a viable option for managing seizures in pediatric patients with autoimmune encephalitis. Clinicians should consider the potential benefits of PER while also recognizing the need for further studies to confirm these preliminary results and address limitations.
Conclusion
Perampanel shows promise in improving seizure outcomes in children with AE-related seizures, warranting further investigation in larger cohorts to validate these findings.
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
